Invenra's proprietary technology combines cell-free expression of full-length antibodies with extreme miniaturization, allowing the screening of unprecedented numbers of full-length antibodies in phenotypic assays. Their team of scientists has expertise in genomics, biochemistry, and bioengineering, and they are developing the next generation of best-in-class biologics, with a focus on multispecific antibodies and their derivatives. Invenra's drug discovery platform is used to optimize bispecific formatting, binding affinities, candidate pairings, and linkers in biologically relevant assays, with a pipeline of immuno-oncology bispecific antibodies currently in preclinical studies.